Latest filing published 03 Jul 2024 for Stoke Therapeutics, Inc., €30k. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
This profile gathers the share dealings of Huw M. Nash in Stoke Therapeutics, Inc., where the filings describe the role as senior executive. The record holds 12 filings, for trades running from 1 June 2021 to 2 July 2024.
The open-market record consists of 1 sale worth €30k, with no purchase. Outside the open market, there are 11 option exercises. 2024 to date brings no purchases and 1 sale.
The newest entry dates from 3 July 2024: an open-market sale of €30k, in Stoke Therapeutics, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
12 of 12 declarations